These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 31410188

  • 1. Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy.
    Zhang Z, Gao W, Zhou L, Chen Y, Qin S, Zhang L, Liu J, He Y, Lei Y, Chen HN, Han J, Zhou ZG, Nice EC, Li C, Huang C, Wei X.
    Theranostics; 2019; 9(17):4878-4892. PubMed ID: 31410188
    [Abstract] [Full Text] [Related]

  • 2. Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.
    Spencer SA, Riley AC, Matthew A, Di Pasqua AJ.
    Ann Pharmacother; 2019 Jun; 53(6):621-626. PubMed ID: 30638036
    [Abstract] [Full Text] [Related]

  • 3. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
    Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, Palmer RH, Hallberg B.
    Oncotarget; 2016 May 17; 7(20):29011-22. PubMed ID: 27049722
    [Abstract] [Full Text] [Related]

  • 4. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
    Passaro A, Prelaj A, Pochesci A, Spitaleri G, Rossi G, Del Signore E, Catania C, de Marinis F.
    Drugs Today (Barc); 2017 Aug 17; 53(8):435-446. PubMed ID: 29119148
    [Abstract] [Full Text] [Related]

  • 5. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
    Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM.
    Clin Cancer Res; 2016 Nov 15; 22(22):5527-5538. PubMed ID: 27780853
    [Abstract] [Full Text] [Related]

  • 6. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C.
    Lung Cancer; 2019 Oct 15; 136():109-114. PubMed ID: 31491676
    [Abstract] [Full Text] [Related]

  • 7. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
    Umbela S, Ghacha S, Matuknauth R, Gause S, Joshee S, Deshmukh RR.
    Curr Probl Cancer; 2019 Dec 15; 43(6):100477. PubMed ID: 31109722
    [Abstract] [Full Text] [Related]

  • 8. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
    Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J, Cai L, Dwight TA, Xu Y, Xu R, Dodd R, Toms A, Parillon L, Lu X, Anjum R, Zhang S, Wang F, Keats J, Wardwell SD, Ning Y, Xu Q, Moran LE, Mohemmad QK, Jang HG, Clackson T, Narasimhan NI, Rivera VM, Zhu X, Dalgarno D, Shakespeare WC.
    J Med Chem; 2016 May 26; 59(10):4948-64. PubMed ID: 27144831
    [Abstract] [Full Text] [Related]

  • 9. Brefeldin A inhibits colorectal cancer growth by triggering Bip/Akt-regulated autophagy.
    Zhou L, Gao W, Wang K, Huang Z, Zhang L, Zhang Z, Zhou J, Nice EC, Huang C.
    FASEB J; 2019 Apr 26; 33(4):5520-5534. PubMed ID: 30668917
    [Abstract] [Full Text] [Related]

  • 10. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.
    Lancet Oncol; 2016 Dec 26; 17(12):1683-1696. PubMed ID: 27836716
    [Abstract] [Full Text] [Related]

  • 11. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
    Hamilton G, Hochmair MJ.
    Expert Opin Pharmacother; 2019 Sep 26; 20(13):1551-1561. PubMed ID: 31328968
    [Abstract] [Full Text] [Related]

  • 12. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.
    N Engl J Med; 2018 Nov 22; 379(21):2027-2039. PubMed ID: 30280657
    [Abstract] [Full Text] [Related]

  • 13. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
    Tu J, Song LT, Liu RR, Zhai HL, Wang J, Zhang XY.
    J Cell Biochem; 2019 Jan 22; 120(1):562-574. PubMed ID: 30191596
    [Abstract] [Full Text] [Related]

  • 14. ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation.
    Gou W, Li Z, Xu X, Shen J, Guo M, Zhou X, Zhang X, Wu Y, Zhai X, Zuo D.
    Biochim Biophys Acta Mol Cell Res; 2020 Jul 22; 1867(7):118712. PubMed ID: 32224191
    [Abstract] [Full Text] [Related]

  • 15. Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC.
    Hoy SM.
    Drugs; 2021 Feb 22; 81(2):267-275. PubMed ID: 33528789
    [Abstract] [Full Text] [Related]

  • 16. Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer.
    Cheng X, Feng H, Wu H, Jin Z, Shen X, Kuang J, Huo Z, Chen X, Gao H, Ye F, Ji X, Jing X, Zhang Y, Zhang T, Qiu W, Zhao R.
    Cancer Lett; 2018 Sep 01; 431():105-114. PubMed ID: 29859300
    [Abstract] [Full Text] [Related]

  • 17. Melatonin Induces Autophagy via Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress Pathway in Colorectal Cancer Cells.
    Chok KC, Koh RY, Ng MG, Ng PY, Chye SM.
    Molecules; 2021 Aug 20; 26(16):. PubMed ID: 34443626
    [Abstract] [Full Text] [Related]

  • 18. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
    Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ.
    J Thorac Oncol; 2018 Oct 20; 13(10):1530-1538. PubMed ID: 29935304
    [Abstract] [Full Text] [Related]

  • 19. Endoplasmic reticulum stress triggered by Soyasapogenol B promotes apoptosis and autophagy in colorectal cancer.
    Wang L, Yun L, Wang X, Sha L, Wang L, Sui Y, Zhang H.
    Life Sci; 2019 Feb 01; 218():16-24. PubMed ID: 30553871
    [Abstract] [Full Text] [Related]

  • 20. Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy.
    Ali R, Arshad J, Palacio S, Mudad R.
    Drug Des Devel Ther; 2019 Feb 01; 13():569-580. PubMed ID: 30804663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.